The current 2019 novel coronavirus disease (COVID-19), an emerging infectious disease, is
undoubtedly the most challenging pandemic in the 21st century. A total of 92,977,768 …

Abstract Coronavirus disease 2019 (COVID-19) has presented a serious worldwide threat to
public health since its emergence in late 2019. From a safety point of view, drug repurposing …

The absence of a specific treatment for SARS-CoV-2 infection led to an intense global effort
in order to find new therapeutic interventions and improve patient outcomes. One important …

Purpose The absence of specific treatments for COVID-19 leads to an intense global effort in
the search for new therapeutic interventions and better clinical outcomes for patients. This …

Since the beginning of the coronavirus disease (COVID)-19 pandemic, the need for effective
treatments for COVID-19 led to the idea of “repurposing” drugs for antiviral treatment …

Serotonin reuptake inhibitors (SRIs) are safe and widely used for a variety of indications
including depressive disorders, anxiety, and chronic pain. Besides inhibiting the serotonin …

Repurposing of currently available drugs is a valuable strategy to tackle the consequences
of COVID-19. Recently, several studies have investigated the effect of psychoactive drugs on …

Background The efficacy of selective serotonin reuptake inhibitors (SSRIs) in the treatment
of acute COVID-19 is still under investigation, with conflicting results reported from …

Mapping non-canonical cellular pathways affected by approved medications can accelerate
drug repurposing efforts, which are crucial in situations with a global impact such as the …

Abstract The World Health Organization has proposed that a search be made for alternatives
to vaccines for the prevention and treatment of COVID-19, with one such alternative being …